The year 2015 saw the approval of six new targeted therapies for the treatment of non-small-cell lung cancer (NSCLC). This analysis discusses recently approved as well as late-stage compounds and examines how different drug classes will affect the NSCLC market.
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
Criminology34
乐空思
无极微光
XQQDD
何政谦
嘉心糖
Hayat
周伯通
干净的琦
ablerHope
Rita
xxx
cc
贪玩的秋柔
无忧
大力的灵雁
白河
互助
ding
皖公网安备34019202002308
